Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Publication date
2021-06
Authors
Nooka, Ajay K
Weisel, Katja
van de Donk, Niels Wcj
Routledge, David
Otero, Paula Rodriguez
Song, Kevin
Quach, Hang
Callander, Natalie
Minnema, Monique
Trudel, Suzanne
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).
Keywords
BCMA, GSK3174998, antibody-drug conjugate, belantamab mafodotin, clinical trial, dostarlimab, feladilimab, multiple myeloma, nirogacestat, platform study, Oncology, Cancer Research, Journal Article
Citation
Nooka, A K, Weisel, K, van de Donk, N W, Routledge, D, Otero, P R, Song, K, Quach, H, Callander, N, Minnema, M C, Trudel, S, Jackson, N A, Ahlers, C M, Im, E, Cheng, S, Smith, L, Hareth, N, Ferron-Brady, G, Brouch, M, de Oca, R M, Paul, S, Holkova, B, Gupta, I, Kremer, B E & Richardson, P 2021, 'Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma : DREAMM-5 study design', Future Oncology, vol. 17, no. 16, pp. 1987-2003. https://doi.org/10.2217/fon-2020-1269